Alliance pancanadienne pharmaceutique (APP) – dernières mises à jour

État Nombre total Résumé
Négociations actives 38 Non liées à l’oncologie: 26
Liées à l’oncologie: 12
Négociations envisagées 26 Non liées à l’oncologie: 13
Liées à l’oncologie: 13
Négociations terminées 505 Avec lettre d’intention: 438
Sans entente: 67
Négociations qui n’ont pas eu lieu 89

Activités de l’APP dans les quatre dernières semaines

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Ogivri BGP Pharma ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kanjinti Amgen Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Ontruzant Organon Canada Inc. Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease; Early Breast Cancer (EBC); Metastatic Breast Cancer (MBC); and Metastatic Gastric Cancer (MGC)
Inrebic Celgene Inc. Treatment of splenomegaly and/or disease-related symptoms in adult patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis, including patients who have been prev
Herzuma Teva Canada Limited Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Trazimera Pfizer Canada ULC Treatment of patients with HER2-positive metastatic breast cancer who have not received prior antiHER2 therapy or chemotherapy for metastatic disease
Kyprolis Amgen Canada Inc. Treatment of multiple myeloma (including relapsed)
Vyxeos Jazz Pharmaceuticals Canada Inc. For the treatment of adults with newly diagnosed therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC).
Vascepa HLS Therapeutics Inc. Ischemic events in statin-treated patients

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines